Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (9): 1086-1094.doi: 10.12092/j.issn.1009-2501.2021.09.016

Previous Articles     Next Articles

Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value

YE Kaili 1, ZHENG Wen 1, YE Qifa 1, YANG Lan 1,2   

  1. 1 Zhongnan Hospital of Wuhan University, Liver Disease Research Institute, Wuhan University, Wuhan University Medical Center, Transplantation of Hubei Province Key Laboratory of Medical Technology, Wuhan 430071, Hubei, China; 2 The Third Xiangya Hospital of Central South University, Engineering Research Center of Transplantation Medicine, Ministry of Health, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China
  • Received:2021-05-12 Revised:2021-08-06 Online:2021-09-26 Published:2021-09-30

PDF (PC)

161

Abstract: Cyclin-dependent kinase 1 is a highly conserved serine/threonine kinase that acts as a checkpoint during mitosis, coordinating and promoting cell cycle progression. CDK1 is significantly upregulated in hepatocellular carcinoma. It is mainly related to p53 signal transduction pathway, LINC00346-miR-199a-3p-CDK1/CyclinB pathway, SNHG16/let-7b-5P/CDC25B/CDK1 pathway and UPF1-SNord52-CDK1 pathway. In this paper, the mechanism of CDK1 involvement in the occurrence and development of hepatocellular carcinoma was systematically elaborated, and the current situation of CDK1 inhibitor targeted treatment of HCC was clarified, which could provide clues and basis for the treatment of HCC with CDK1 as the target.

Key words: cyclin-dependent kinase 1, cyclin, hepatocellular carcinoma, cell cycle

CLC Number: